MedTrace Logo

The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19

NCT05848427 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-04-05

No results posted yet for this study

Summary

The coronavirus disease 2019 (COVID-19) has spread rapidly and caused a global pandemic, as defined by the WHO, within a short period of time. The prognostic of disease severity is still a challenge and early identification of risk factors to be involved in its progression is of high importance. The scoring of variables related to worse outcomes is key for a targeted and/or advanced protocol. Besides, the need for a predictive-wide model is mandatory for hospitalized unvaccinated patients to avoid any delay in the characterization of severe illness and the development of complications. The LUSZ COVID-19 Severity Index was developed as a predictive tool based on \>100 risk factors/biomarkers, that could effectively identify high-risk patients and prevent mortality.

Conditions

Interventions

OTHER

LUSZ P

LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.

Sponsors & Collaborators

  • Hospital Saydet Zgharta University Medical Center

    collaborator UNKNOWN

  • Lebanese University

    lead OTHER

Principal Investigators

  • Nehman Makdissy, Professor · Lebanese University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-28
Primary Completion
2025-12-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05848427 on ClinicalTrials.gov